



Q2 and H1 2018 Results

August 22, 2018


Presented by:
René Goehrum
President and CEO

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results.


By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.


Sales, EBITDA and NIAT Quarter Ended June 30th



Sales, EBITDA and NIAT Six Months Ended June 30th



Pharmaceutical Sales By Quarter



- **Q2 2018 pharmaceutical sales of \$5.5 million increased 9% over Q2 2017**
- Record quarterly Canadian pharmaceutical sales of \$5.0 million in Q2 2018 increased 16% over Q2 2017
 - Q2 2018 vs. Q2 2017 Canadian sales volumes (units):
 - FeraMAX[®] 150 +10%
 - FeraMAX[®] Powder +14%
 - RepaGyn[®] +23%
 - Cathejell[®] +20%
 - Aguetant System[®] +184%
- Q2 2018 International FeraMAX[®] sales of \$511k decreased by 31% versus Q2 2017
 - Quarterly variability in sales
 - Added distribution complexities and risks vs. Canadian business

- **H1 2018 pharmaceutical sales of \$9.9 million increased 13% over H1 2017**
 - H1 2018 Canadian pharmaceutical sales of \$8.8 million increased 14% over H1 2017
 - H1 2018 vs. H1 2017 Canadian sales volumes (units):
 - FeraMAX[®] 150 +10%
 - FeraMAX[®] Powder +10%
 - RepaGyn[®] +22%
 - Cathejell[®] +21%
 - Aguetant System[®] +93%
 - H1 2018 International FeraMAX[®] sales of \$1,077k increased by 4% versus H1 2017

- Long selling cycle, but more hospitals adopting Cysview®
- Implementation update
 - 7 hospital sites currently operational with Cysview® vs. 2 sites at end of Q1 2018
 - 4 new sites added in Q2 2018, 1 new site added in July 2018
 - 5 operational sites placed first orders for Cysview® in 2018
 - 7 additional hospital sites have completed successful evaluations of Cysview®
 - 2 further hospital sites have decided to implement Cysview® without evaluation
- Sales volume (units) +80% in H1 2018 vs. H1 2017 (comparison to low base)

CYSVIEW®
HEXAMINOLEVULINATE HCL

- January 2018: Mr. Larry Andrews and Ms. Sara Elford appointed to Board of Directors (replacing Director retirements)
- May 2018: Mr. Joseph Arcuri elected to Board of Directors @ May 29, 2018 AGM (replacing Director retirement)
- May 2018: FeraMAX® named #1 recommended iron supplement brand in Canada for 3rd consecutive year
 - Recommended #1 by 43% of physicians and by 35% of pharmacists surveyed



- Q2 2018: Record quarter for Hospital Business which delivered 71% revenue growth vs. Q2 2017

Growth driven by organic growth of existing portfolio **plus** incremental growth from new products and new international markets:

Existing product portfolio growth drivers

- FeraMAX[®]: Canada and International (existing markets)
- CYSVIEW[®]
- Cathejell[®] Jelly 2%
- RepaGyn[®]
- Aguetant System[®]

New products and new markets

- FeraMAX[®] International (Sales to new markets)
- 2 Cardiovascular Rx products; upon Health Canada approval
- Women's Health Rx product; upon Health Canada approval

New in-licensed products

- To be announced – active deal funnel
- Portfolio expansion – core to our strategy

BioSyent Inc.

Interim Unaudited Condensed Consolidated Statements of Financial Position

AS AT	June 30, 2018	December 31, 2017	% Change
ASSETS			
Trade and other receivables	\$ 2,507,474	\$ 2,236,695	12%
Inventory	1,734,295	908,825	91%
Prepaid expenses and deposits	215,454	147,326	46%
Income tax recoverable	54,543	71,924	-24%
Derivative asset	146,179	-	
Cash, cash equivalents and short-term investments	21,014,159	19,338,435	9%
Current Assets	25,672,104	22,703,205	13%
Equipment	273,197	290,926	-6%
Intangible assets	1,928,250	1,670,210	15%
Loans receivable	395,813	393,860	
Deferred tax asset	44,246	46,647	-5%
TOTAL NON CURRENT ASSETS	2,641,506	2,401,643	10%
TOTAL ASSETS	\$ 28,313,610	\$ 25,104,848	13%
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities	\$ 2,771,447	\$ 2,615,594	6%
Deferred tax liability	358,966	276,327	30%
Long term debt	-	-	0%
Total Equity	25,183,197	22,212,927	13%
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 28,313,610	\$ 25,104,848	13%

Working Capital of
\$22.9 million
+14% from Dec. 31, 2017


Cash and ST investments
of \$21.0 million
+9% from Dec. 31, 2017

Continuing to build
Balance Sheet for
deployment opportunities


Zero Debt

June 30 Cash Balance and H1 Cash Generation (“CG”)

- Management actively seeking new product acquisition opportunities
 - 15 products evaluated in H1 2018



Return on Equity (“ROE”)



Earnings Per Share

Last 8 Quarters

Quarter	NIAT	Diluted EPS
Q2 2018	\$1,620,233	\$ 0.11
Q1 2018	\$1,143,130	\$ 0.08
Q4 2017	\$1,457,228	\$ 0.10
Q3 2017	\$1,294,575	\$ 0.09
Q2 2017	\$1,552,918	\$ 0.11
Q1 2017	\$ 901,556	\$ 0.06
Q4 2016	\$1,094,822	\$ 0.08
Q3 2016	\$1,247,380	\$ 0.08

\$0.38

\$0.33

TTM EPS Growth **+15%**

Annual





Stock Information August 20, 2018

Exchange & Trading Symbol:
August 20, 2018 closing stock price (CAD)
52 Week Hi / Low:
Current Shares:
Warrants:
Options:
Fully Diluted:
P/E Ratio (TTM):
P/B Ratio:

TSXV: RX
\$9.76
\$8.00 / \$11.00
14,519,603
0
153,117
14,672,720
25.97
5.63

Thank you

www.BioSyent.com

www.sedar.com

www.tmxmoney.com

www.BioSyentPFS-System.ca

www.Cathejell.ca

www.CYSVIEW.ca

www.FeraMAX.com

www.Proktis-M.ca

www.RepaGyn.ca